Compare Stocks: CPIX, CGC, ASMB, and FENC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$32.95 +10.0%	$26.09	$20.23 ▼ $39.71	$475.98M	1.1	162,716 shs	559,105 shs
CGC Canopy Growth	$1.02 +1.0%	$0.96	$0.84 ▼ $2.38	$452.90M	0.81	2.95 million shs	2.30 million shs
CPIX Cumberland Pharmaceuticals	$7.79 -1.4%	$6.67	$1.85 ▼ $8.45	$118.37M	0.08	137,796 shs	57,819 shs
FENC Adherex Technologies	$11.72 -2.8%	$10.25	$5.65 ▼ $13.25	$422.80M	1.09	183,730 shs	106,940 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+10.68%	+13.23%	+11.92%	+4.54%	+21.01%
CGC Canopy Growth	-1.46%	+8.35%	+5.35%	-2.88%	-38.41%
CPIX Cumberland Pharmaceuticals	-0.13%	+2.86%	+13.02%	+44.42%	+169.62%
FENC Adherex Technologies	+1.94%	+11.25%	+8.06%	+23.69%	+32.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$32.95 +10.0%	$26.09	$20.23 ▼ $39.71	$475.98M	1.1	162,716 shs	559,105 shs
CGC Canopy Growth	$1.02 +1.0%	$0.96	$0.84 ▼ $2.38	$452.90M	0.81	2.95 million shs	2.30 million shs
CPIX Cumberland Pharmaceuticals	$7.79 -1.4%	$6.67	$1.85 ▼ $8.45	$118.37M	0.08	137,796 shs	57,819 shs
FENC Adherex Technologies	$11.72 -2.8%	$10.25	$5.65 ▼ $13.25	$422.80M	1.09	183,730 shs	106,940 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+10.68%	+13.23%	+11.92%	+4.54%	+21.01%
CGC Canopy Growth	-1.46%	+8.35%	+5.35%	-2.88%	-38.41%
CPIX Cumberland Pharmaceuticals	-0.13%	+2.86%	+13.02%	+44.42%	+169.62%
FENC Adherex Technologies	+1.94%	+11.25%	+8.06%	+23.69%	+32.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.57	Moderate Buy	$44.00	33.54% Upside
CGC Canopy Growth	2.20	Hold	N/A	N/A
CPIX Cumberland Pharmaceuticals	1.00	Sell	N/A	N/A
FENC Adherex Technologies	2.57	Moderate Buy	$16.40	39.93% Upside

Current Analyst Ratings Breakdown

Latest CPIX, CGC, ASMB, and FENC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	FENC Adherex Technologies	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00 ➝ $18.00
8/12/2026	FENC Adherex Technologies	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $16.00
7/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	ASMB Assembly Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	FENC Adherex Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	CPIX Cumberland Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/15/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$40.00 ➝ $45.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$72.30M	7.24	N/A	N/A	$13.04 per share	2.53
CGC Canopy Growth	$251.01M	1.82	N/A	N/A	$1.11 per share	0.92
CPIX Cumberland Pharmaceuticals	$44.52M	2.62	$0.36 per share	21.54	$1.14 per share	6.83
FENC Adherex Technologies	$44.64M	9.20	N/A	N/A	$1.04 per share	11.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$6.12M	-$0.11	32.30	N/A	N/A	-0.06%	-0.02%	-0.02%	N/A
CGC Canopy Growth	-$190.29M	-$0.45	N/A	N/A	N/A	-65.33%	-21.91%	-14.34%	N/A
CPIX Cumberland Pharmaceuticals	-$2.84M	-$0.71	N/A	N/A	N/A	-34.40%	-28.81%	-9.25%	N/A
FENC Adherex Technologies	-$9.74M	-$0.13	N/A	11.96	N/A	-6.09%	-6.93%	-2.48%	N/A

Latest CPIX, CGC, ASMB, and FENC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/13/2026	Q2 2026	FENC Adherex Technologies	$0.02	$0.05	+$0.03	$0.05	$16.21 million	$17.87 million
8/7/2026	Q1 2027	CGC Canopy Growth	-$0.04	-$0.02	+$0.02	-$0.02	$58.21 million	$142.62 million
8/4/2026	Q2 2026	CPIX Cumberland Pharmaceuticals	-$0.13	-$0.20	-$0.07	-$0.29	$8.50 million	$0.17 million
6/15/2026	Q4 2026	CGC Canopy Growth	-$0.06	-$0.17	-$0.11	-$0.05	$53.43 million	$51.22 million
5/14/2026	Q1 2026	FENC Adherex Technologies	-$0.02	$0.01	+$0.03	$0.01	$13.90 million	$15.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A

Latest CPIX, CGC, ASMB, and FENC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/13/2026	CPIX Cumberland Pharmaceuticals		$1.50			7/23/2026	7/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	6.65	6.65
CGC Canopy Growth	0.31	3.04	2.64
CPIX Cumberland Pharmaceuticals	N/A	0.96	0.79
FENC Adherex Technologies	N/A	6.98	6.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
CGC Canopy Growth	3.33%
CPIX Cumberland Pharmaceuticals	15.51%
FENC Adherex Technologies	55.51%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	3.50%
CGC Canopy Growth	0.16%
CPIX Cumberland Pharmaceuticals	42.07%
FENC Adherex Technologies	10.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	100	15.89 million	15.34 million	Optionable
CGC Canopy Growth	1,128	448.42 million	447.70 million	Optionable
CPIX Cumberland Pharmaceuticals	80	14.98 million	8.68 million	Optionable
FENC Adherex Technologies	10	35.06 million	31.30 million	Optionable

CPIX, CGC, ASMB, and FENC Headlines

Recent News About These Companies

Adherex Technologies (NASDAQ:FENC) Earns Buy Rating from B. Riley Financial

August 14 at 2:24 AM | americanbankingnews.com

Adherex Technologies (NASDAQ:FENC) Stock Price Expected to Rise, Wedbush Analyst Says

August 14 at 2:24 AM | americanbankingnews.com

B. Riley Financial Reaffirms "Buy" Rating for Adherex Technologies (NASDAQ:FENC)

August 12 at 12:59 PM | marketbeat.com

Wedbush Boosts Adherex Technologies (NASDAQ:FENC) Price Target to $16.00

August 12 at 12:17 PM | marketbeat.com

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

August 12 at 10:56 AM | zacks.com

Adherex Technologies Q2 Earnings Call Highlights

August 11 at 11:04 AM | marketbeat.com

Adherex Technologies (NASDAQ:FENC) Announces Earnings Results, Beats Estimates By $0.03 EPS

August 11 at 10:55 AM | marketbeat.com

Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates

August 11 at 9:21 AM | zacks.com

Adherex Technologies (FENC) Projected to Post Quarterly Earnings on Thursday

August 6, 2026 | americanbankingnews.com

Adherex Technologies (FENC) Projected to Release Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

August 5, 2026 | globenewswire.com

Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 4, 2026 | americanbankingnews.com

Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of "Moderate Buy" from Analysts

August 4, 2026 | marketbeat.com

Adherex Technologies (NASDAQ:FENC) Stock Price Up 0.2% - Here's Why

August 3, 2026 | marketbeat.com

Is the Options Market Predicting a Spike in Adherex Technologies Stock?

July 6, 2026 | zacks.com

Fennec Announces Results of Annual Meeting

June 10, 2026 | globenewswire.com

Adherex Technologies' PEDMARK push targets larger AYA market after record quarter

May 23, 2026 | msn.com

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

May 21, 2026 | globenewswire.com

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026 | globenewswire.com

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2026 Earnings Call Transcript

May 15, 2026 | insidermonkey.com

Do options traders know something about Adherex Technologies stock we don't?

May 14, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX, CGC, ASMB, and FENC Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$32.95 +3.00 (+10.02%)

Closing price 04:00 PM Eastern

Extended Trading

$32.12 -0.83 (-2.50%)

As of 07:34 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Canopy Growth NASDAQ:CGC

$1.02 +0.01 (+0.99%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 -0.02 (-1.47%)

As of 07:59 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Cumberland Pharmaceuticals NASDAQ:CPIX

$7.79 -0.11 (-1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$7.80 +0.00 (+0.06%)

As of 07:34 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Adherex Technologies NASDAQ:FENC

$11.72 -0.34 (-2.82%)

Closing price 04:00 PM Eastern

Extended Trading

$11.72 0.00 (0.00%)

As of 07:34 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPIX, CGC, ASMB, and FENC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPIX, CGC, ASMB, and FENC Earnings

Compare Dividends

Latest CPIX, CGC, ASMB, and FENC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPIX, CGC, ASMB, and FENC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX, CGC, ASMB, and FENC Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Canopy Growth NASDAQ:CGC

Cumberland Pharmaceuticals NASDAQ:CPIX

Adherex Technologies NASDAQ:FENC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPIX, CGC, ASMB, and FENC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPIX, CGC, ASMB, and FENC Earnings

Compare Dividends

Latest CPIX, CGC, ASMB, and FENC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPIX, CGC, ASMB, and FENC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX, CGC, ASMB, and FENC Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Canopy Growth NASDAQ:CGC

Cumberland Pharmaceuticals NASDAQ:CPIX

Adherex Technologies NASDAQ:FENC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools